Abstract 2187
Background
The number of Chinese cancer survivors is increasing due to the trend of an aging population and improved cancer survival. It is urgently required to estimate the health status of cancer survivors and provide scientific evidence for future health care reform. This study aimed to evaluate the general health status of cancer survivors older than 45 years in China.
Methods
We identified cancer survivors (n = 354) and participants without cancer (n = 16,664) in the China Health and Retirement Longitudinal Study (CHARLS). Physical and mental health information collected by questionnaire were compared between cancer survivors and cancer-free controls.
Results
The mean age of cancer survivors was 61.0 years. More cancer survivors were female (68.9% vs. 52.3%, P < 0.001) and lived in a rural region (43.8% vs. 38.4%, P = 0.039) than those without cancer. Cancer survivors and participants without cancer did not show significant differences in age, marital status, education or BMI. The health status of middle-aged and older cancer survivors are shown in the table. Cancer survivors had more concomitant chronic diseases than participants without cancer (2.75 vs. 2.00, P < 0.001). The current health condition reported by cancer survivors themselves was poorer than no cancer group (3.87 vs. 3.38, P < 0.001). The daily activity score was higher in the cancer group (3.53 vs. 2.39, P < 0.001), which indicated that cancer survivors had more difficulties in their daily life than other middle-aged and older participants. There was no statistically significant difference in cognitive function between these two groups even after adjustment (12.61 vs. 12.90, P = 0.612). Cancer survivors had more depressive symptoms than participants without cancer after adjustment (10.07 vs. 8.01, P = 0.003).Table: 1649P
Health status of middle-aged and older cancer survivors and participants without cancer from the CHARLS
Characteristic | Total (N = 17,018) | Cancer survivors (n = 354) | No cancer (n = 16,664) | P value | P value† |
---|---|---|---|---|---|
Number of concomitant chronic diseases, mean ± SD | 2.02 ± 1.70 | 2.75 ± 2.13 | 2.00 ± 1.69 | <0.001 | |
Self-reported health score (1-5), mean ± SD | 3.39 ± 0.38 | 3.87 ± 0.82 | 3.38 ± 0.87 | <0.001 | <0.001 |
Daily activity, mean ± SD | 2.41 ± 3.36 | 3.53 ± 3.85 | 2.39 ± 3.35 | <0.001 | <0.001 |
Cognitive function, mean ± SD | 12.89 ± 5.69 | 12.61 ± 5.60 | 12.90 ± 5.69 | 0.629 | 0.612 |
Depression, mean ± SD | 8.05 ± 6.41 | 10.07 ± 7.06 | 8.01 ± 6.39 | <0.001 | 0.003 |
Adjusted for age, sex, region, and number of concomitant chronic diseases.
Conclusions
The health status of middle-aged and older cancer survivors is poor in China. High-quality and cost-effective supportive care for these individuals is needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China (No. 61435001) and CAMS Innovation Fund for Medical Sciences (No. 2016-I2M-1-001, No. 2017-I2M-4-003).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2553 - Interim analysis of a phase Ib study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild type melanoma progressing on prior anti-PD-L1 therapy
Presenter: Shahneen Sandhu
Session: Poster Display session 3
Resources:
Abstract
2743 - The Impact of Targeted Therapies and Immunotherapy in Melanoma Brain Metastases: a Systematic Review and Meta-Analysis
Presenter: Mario Mandala
Session: Poster Display session 3
Resources:
Abstract
5479 - Intracranial Anti-Tumor Activity in Melanoma Brain Metastases with Encorafenib Plus Binimetinib: A Multicenter, Retrospective Analysis
Presenter: Jose Lutzky
Session: Poster Display session 3
Resources:
Abstract
3560 - Outcomes of Patients with Melanoma Brain Metastases (MBM) Treated with Standard of Care Therapy After Being Excluded from MBM-Specific Clinical Trials
Presenter: Kourtney Holbrook
Session: Poster Display session 3
Resources:
Abstract
3175 - The analysis of current treatment outcomes in melanoma patients with brain metastases
Presenter: Joanna Placzke
Session: Poster Display session 3
Resources:
Abstract
4550 - A multivariate model to define prognostic groups among patients with melanoma brain metastases: a 10-year retrospective cohort study
Presenter: Giacomo Pelizzari
Session: Poster Display session 3
Resources:
Abstract
4191 - The immune landscape of melanoma significantly influences survival in patients with highly mutated tumors.
Presenter: Robert Ferguson
Session: Poster Display session 3
Resources:
Abstract
1625 - Final Results from Phase II of Combination with Canerpaturev (formerly HF10), an Oncolytic Viral Immunotherapy, and Ipilimumab in Unresectable or Metastatic Melanoma in 2nd-or later line treatment
Presenter: Kenji Yokota
Session: Poster Display session 3
Resources:
Abstract
5346 - Evaluating polygenic risk score prediction model for melanoma prognosis
Presenter: Miriam Potrony
Session: Poster Display session 3
Resources:
Abstract
5477 - Impact of sarcopenia in patients with metastatic melanoma treated with immunotherapy
Presenter: Maria Grazia Vitale
Session: Poster Display session 3
Resources:
Abstract